Rachel Webster

Hot off the press! Find out more about the small-cell lung cancer pipeline and market from DRG experts @NatRevDrugDisc @RWebsterDRG #DRGOncology #SCLC lnkd.in/ekTRTFf lnkd.in/e-xS-Ys

Check out my latest article: The small-cell lung cancer drug market linkedin.com/pulse/small-ce… via @LinkedIn

Check out our latest article: DRG expert insights on tumour-agnostic therapies linkedin.com/pulse/drg-expe… via @LinkedIn

More analysis and insights from @DRGinsights experts @KhurramOncology @am_looney @RWebsterDRG Find out more about tumour-agnostic therapies #DRGOncology

The approval (and uptake) of 9 drugs since 2017 is fuelling rapid growth of the AML market. These drugs are expected to occupy 85% of the market in 2028. Find out more @DRGinsights #DRGOncology Read our latest @NatRevDrugDisc article nature.com/articles/d4157…

Despite the small number of patients (2% of cancers), drugs for multiple myeloma were worth nearly $14B in 2017. @DRGinsights explains drivers and how that market will change in the next 10 years @NatRevDrugDisc nature.com/articles/d4157…

sBLAs for #Keytruda dosing every 6 weeks have been accepted by the #FDA. In the US Keytruda is currently dosed every 3 weeks and #Opdivo is dosed every 2 weeks or every 4 weeks. Convenience of dosing schedules can have a big influence on drug selection! #DRGOncology

For readers interested in the R&D landscape for antibody-drug conjugates such as the one involved in AstraZeneca's multi-billion dollar collaboration with Daiichi Sankyo, here's a recent review rdcu.be/btRwK

This new article analyses the pipeline and market for drugs to treat multiple myeloma go.nature.com/2BCAGtF

Read our latest @NatRevDrugDisc article on the Multiple Myeloma Drug Market. lnkd.in/enaujrG @RWebsterDRG #DRGOncology For more expert insights check out DRGOncology.com lnkd.in/epfHs2T

What does #DRGOncology expect for the #oncology market in 2019? Check out our #video prediction here: tinyurl.com/yydqbhn6

CAR T-Cell Therapies In The EU5: What Can We Expect From Payers? Latest insights from #DRGOncology experts @RWebsterDRG find the article here: DRGOncology.com

ESMO 2018: Expanding Horizons in Advanced Breast Cancer. More insights from the #DRGOncology experts. Check out more insights at DRGOncology.com decisionresourcesgroup.com/drg-blog/drug-…

DRG's @RWebsterDRG M.Sc., D.Phil discusses the rapid growth of the oncology drug market and advances in oncology treatments with PharmaVOICE. #DRGOncology Read more here: pharmavoice.com/article/2018-1…

Analysis of the hepatocellular carcinoma pipeline and market go.nature.com/2M0h3hu

Read about the latest news and our expert analysis of the #Hepatocellular Carcinoma Market in our latest @NatRevDrugDis article @JNBDawkins @RWebsterDRG #DRGOncology

Working in oncology? Subscribe to DRGOncology.com for free and receive thought #leadership, #infographics, updates, and #opinions on the #oncology landscape. @DRGinsights #DRGOncology

Big blow to RCC and Opdivo/Yeroy in EU. "They didn't feel we'd demonstrated the contribution of components sufficiently". Is it Re no mono arm? Favourable risk data? Shock given it's 37% reduced risk of DEATH & 15% higher response! #DRGOncology $BMY #KCSM reuters.com/article/us-bri…